Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture-Reference-Cited by-同舟云学术

Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture

Published:2020-08 Issue: Volume:115 Page:104697
ISSN:0273-2300
Container-title:Regulatory Toxicology and Pharmacology
language:en
Short-container-title:Regulatory Toxicology and Pharmacology

Author:

Turk James R.,Deaton Aimee M.,Yin Jun,Stolina Marina,Felx Melanie,Boyd Gabrielle,Bienvenu Jean-Guy,Varela Aurore,Guillot Martin,Holdsworth Gill,Wolfreys Alison,Dwyer Denise,Kumar Sheetal V.,de Koning Emily M.,Qu Yusheng,Engwall Michael,Locher Kathrin,Ward Lucas D.,Glaus Charles,He Yudong D.,Boyce Rogely Waite

Funder

Amgen Inc.

Astellas

UCB Pharma

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference69 articles.

1. Human scavenger protein AIM increases foam cell formation and CD36-mediated oxLDL uptake;Amezaga;J. Leukoc. Biol.,2014

2. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism;Atkins;J. Bone Miner. Res.,2011

3. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST);Balemans;Hum. Mol. Genet.,2001